$0.40
+0.03 (+6.92%)
Open$0.37
Previous Close$0.37
Day High$0.43
Day Low$0.36
52W High$17.80
52W Low$0.36
Volume—
Avg Volume49.84M
Market Cap2.15M
P/E Ratio—
EPS$-8.24
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+4,833.6% upside
Current
$0.40
$0.40
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 14.25M | 491.6K | 478.0K |
| Net Income | -166,699,875 | -25,839 | -25,168 |
| Profit Margin | -1,169.7% | -5.3% | -5.3% |
| EBITDA | -161,654,369 | -32,660 | -28,783 |
| Free Cash Flow | — | -24,331 | -23,138 |
| Rev Growth | — | +16.5% | +3.1% |
| Debt/Equity | 0.47 | 0.13 | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |